Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/10/2014 09/11/2014 09/12/2014 09/15/2014 09/16/2014 Date
69.5(c) 70.37(c) 72.55(c) 71.95(c) 73.46(c) Last
787 857 489 311 902 790 856 469 717 798 Volume
+5.54% +1.25% +3.10% -0.83% +2.10% Change
More quotes
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference. It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
Surperformance© rating of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 34,1 M
EBIT 2014 -314 M
Net income 2014 -334 M
Finance 2014 737 M
Yield 2014 -
Sales 2015 49,6 M
EBIT 2015 -192 M
Net income 2015 -209 M
Finance 2015 698 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 143x
EV / Sales 2015 99,0x
Capitalization 5 609 M
More Financials
Latest news on ALNYLAM PHARMACEUTICALS, I
3h ago ALNYLAM PHARMACEUTICALS : Bolsters Pipeline with ALN-AGT for the Treatment of Hy..
1d ago ALNYLAM PHARMACEUTICALS : Scholar Rock Announces Appointment of Leading Clinicia..
1d ago ALNYLAM PHARMACEUTICALS : Presents New Pre-Clinical Data with ALN-CC5, a Subcuta..
1d ago ALNYLAM PHARMACEUTICALS : Assigned Patent
2d ago ALNYLAM PHARMACEUTICALS : Strengthens Management Team with New Key Appointments
5d ago ALNYLAM PHARMACEUTICALS : Broadens Pipeline with ALN-AGT, a Subcutaneously Admin..
09/03 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at Morgan Stanley Global Healt..
08/27 ALNYLAM PHARMACEUTICALS : Receives Notice of Allowance from United States Patent..
08/22 ALNYLAM PHARMACEUTICALS : Assigned Patent
08/20 ALNYLAM PHARMACEUTICALS : Receives Notice of Allowance from United States Patent..
08/19 ALNYLAM PHARMACEUTICALS : Updates on Second Quarter Results
08/14 ALNYLAM PHARMACEUTICALS : Posts Second Quarter Results
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
Alnylam Pharmaceuticals, I : Income Statement Evolution
More Financials
EPS Revisions
Alnylam Pharmaceuticals, I : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF